Medtronic plc (MDT) Operating Cash Flow CAGR:0.41%(TTM)
The operating cash flow cagr for Medtronic plc (MDT) is +0.41% over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow CAGR for Medtronic plc (MDT) stock is 0.41% over the past 12 months. The 3 year CAGR is 8.45% and the 5 year CAGR is 4.08%.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash Medtronic plc generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
MDT Operating Cash Flow CAGR Chart
Medtronic plc (MDT)
MDT Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
MDT Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | $7.04B | $7.33B | +$286.00M | +4.06% | +4.06% |
| 2025 | $6.79B | $7.04B | +$257.00M | +3.79% | +3.79% |
| 2024 | $6.04B | $6.79B | +$748.00M | +12.39% | +12.39% |
| 2023 | $7.35B | $6.04B | $-1.31B | -17.79% | -17.79% |
| 2022 | $6.24B | $7.35B | +$1.11B | +17.72% | +17.72% |
| 2021 | $7.23B | $6.24B | $-994.00M | -13.74% | -13.74% |
| 2020 | $7.01B | $7.23B | +$227.00M | +3.24% | +3.24% |
| 2019 | $4.68B | $7.01B | +$2.32B | +49.59% | +49.59% |
| 2018 | $6.88B | $4.68B | $-2.20B | -31.92% | -31.92% |
| 2017 | $5.22B | $6.88B | +$1.66B | +31.85% | +31.85% |
| 2016 | $4.90B | $5.22B | +$316.00M | +6.45% | +6.45% |
| 2015 | $4.96B | $4.90B | $-57.00M | -1.15% | -1.15% |
| 2014 | $4.88B | $4.96B | +$76.00M | +1.56% | +1.56% |
| 2013 | $4.38B | $4.88B | +$502.00M | +11.46% | +11.46% |
| 2012 | $3.74B | $4.38B | +$640.00M | +17.11% | +17.11% |
| 2011 | $4.13B | $3.74B | $-390.00M | -9.44% | -9.44% |
| 2010 | $3.88B | $4.13B | +$253.00M | +6.52% | +6.52% |
| 2009 | $3.49B | $3.88B | +$389.00M | +11.15% | +11.15% |
| 2008 | $2.98B | $3.49B | +$510.00M | +17.12% | +17.12% |
| 2007 | $2.21B | $2.98B | +$771.60M | +34.96% | +34.96% |
| 2006 | $2.82B | $2.21B | $-612.00M | -21.71% | -21.71% |
| 2005 | $2.85B | $2.82B | $-26.40M | -0.93% | -0.93% |
| 2004 | $2.08B | $2.85B | +$767.60M | +36.94% | +36.94% |
| 2003 | $1.59B | $2.08B | +$488.00M | +30.69% | +30.69% |
| 2002 | $1.83B | $1.59B | $-241.30M | -13.17% | -13.17% |
| 2001 | $1.04B | $1.83B | +$789.50M | +75.77% | +75.77% |
| 2000 | $455.30M | $1.04B | +$586.70M | +128.86% | +128.86% |
| 1999 | $590.10M | $455.30M | $-134.80M | -22.84% | -22.84% |
| 1998 | $463.60M | $590.10M | +$126.50M | +27.29% | +27.29% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q4 2026 | $2.57B | -6.2% | +1.8% |
| Q3 2026 | $2.74B | +196.6% | +6.7% |
| Q2 2025 | $925.00M | -15.0% | -3.4% |
| Q1 2025 | $1.09B | -57.0% | +10.3% |
| Q4 2025 | $2.53B | -1.7% | -9.0% |
| Q3 2025 | $2.57B | +168.5% | +4.0% |
| Q2 2024 | $958.00M | -2.8% | +44.9% |
| Q1 2024 | $986.00M | -64.5% | +12.7% |
| Q4 2024 | $2.78B | +12.2% | +12.9% |
| Q3 2024 | $2.47B | +274.3% | +57.2% |
| Q2 2023 | $661.00M | -24.5% | -28.3% |
| Q1 2023 | $875.00M | -64.4% | -19.2% |
| Q4 2023 | $2.46B | +56.3% | +19.6% |
| Q3 2023 | $1.57B | +70.7% | -29.4% |
| Q2 2022 | $922.00M | -14.9% | -47.9% |
| Q1 2022 | $1.08B | -47.4% | -16.2% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha